Daniel Barber
CEO, President & DirectorMr. Daniel Barber, also known as Dan, is the Chief Executive Officer, President and Director at Aquestive Therapeutics, Inc. since May 17, 2022 and served as its Senior Vice President since April 2014 until May 17, 2022 and served as its Chief Strategy and Development Officer until May 2019 and served as its Chief Operating Officer since May 2019 until May 17, 2022. Mr. Barber served as Vice President of Value Creation of MonoSol Rx Inc. (formerly MonoSol RX, LLC). Mr. Barber served as Vice President of Business Development and Alliance Management of Aquestive Therapeutics, Inc (also known as MonoSol RX, LLC). Mr. Barber joined MonoSol Rx in July 2007. He served as the Executive of Corporate, Business & Product Development at Aquestive Therapeutics, Inc. April 2014. Prior to joining MonoSol Rx, Mr. Barber held Managerial positions with Quest Diagnostics and Xerox Corporation. While at Quest Diagnostics, Mr. Barber held positions in their corporate planning and international divisions. During his time at Xerox Corporation, Mr. Barber held several finance roles in their North America division. In 2010, Mr. Barber had executive oversight of launch activities for first two FDA approved products. Mr. Barber received his BA degree from State University of New York and an MBA from Seton Hall University.
Positions
- Company NameAquestive Therapeutics, Inc.Stock CodeAQSTPositionCEO, President & DirectorColleagues
- GBGregory Bailey BrownIndependent Chairman of the Board
- AEA. Ernest TothSenior VP & CFO
- LJLori J. BraenderCorporate Secretary
- CJCassie JungChief Operating Officer
- TAThomas A. ZalewskiChief Legal Officer & Chief Compliance Officer
- JSJohn Shannon CochranIndependent Vice Chairman of the Board
- TETimothy E. MorrisIndependent Director
- JKJulie KropIndependent Director
